Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
Results of antibiotic treatment in 144 febrile episodes during drug-induced granulocytopenia are reported. 63 episodes were treated with ceftazidime plus amikacin and 81 with ceftriaxone (CFX) using single daily doses combined with amikacin either divided in three doses (CFX-1 group) or administered as single doses (CFX-2 group). The response rates were 51, 80, and 57% respectively. In this study CFX was more effective than ceftazidime and amikacin provided better results when administered using the standard 8-hour scheduling.
Leoni
F
F
Cattedra e Divisione di Ematologia, USL 10/D, Firenze, Italia.
Ciolli
S
S
Pascarella
A
A
Fanci
R
R
Caporale
R
R
Rossi Ferrini
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy*
D002443:Ceftriaxone; D000583:Amikacin; D002442:Ceftazidime